99Tcm-MIBI显像对肿瘤多药耐药检测的应用

The application of 99Tcm-MIBI imaging to detect multidrug resistance

  • 摘要: MDR(多药耐药)是目前肿瘤化疗失败的主要原因,对MDR的检测可以帮助化疗决策的制定,从而使肿瘤患者得到更有效的治疗。99Tcm-MIBI(99Tcm-甲氧基异丁基异腈)是mdr1基因编码的P-gp(P-糖蛋白)和MRP(多药耐药相关蛋白)的转运底物,肿瘤细胞内99Tcm-MIBI摄取减低表明其P-gp的高表达,并与MRP的表达相关。因此,99Tcm-MIBI显像可在治疗前预测对化疗的反应,并为选择更有效的化疗策略提供依据。

     

    Abstract: Multidrug resistance is the main cause of chemotherapy failure,To detect multidrug resistance is helpful to develop chemotherapy regimens and more effective treatment of patients with tumors. 99Tcm-sestamibi is a transport sub-strate of mdr1-encoded P-glycoprotein and MRP.The lower 99Tcm-sestamibi accumulation indicates the higher expression of P-glycoprotein in tumor cells.It is also related to the expression of MRP.As a result,response to chemotherapy can be estimated before starting treatment by means of 99Tcm-sestamibi imaging and more effective protocol can be chosen.

     

/

返回文章
返回